Araújo Maísa Miranda, Vogado Carolina de Oliveira, Mendes Marcela Moraes, Gonçalves Vivian Siqueira Santos, Botelho Patrícia Borges
Graduate Program in Human Nutrition, Department of Nutrition, University of Brasília, Brasília, Federal District, Brazil.
Graduate Program in Public Health, Department of Nutrition, Faculty of Health Science, University of Brasília, Brasília, Federal District, Brazil.
Nutr Rev. 2022 May 9;80(6):1619-1633. doi: 10.1093/nutrit/nuab109.
The effects of probiotics on gastrointestinal (GI) symptoms have been increasingly investigated, particularly that of Bifidobacterium animalis. Clinical trials so far have shown differing evidence regarding these effects in healthy adults.
To synthesize the published evidence on the effects of B. animalis subspecies lactis on GI symptoms (GIS) in healthy adults.
A search of the Medline, Embase, Lilacs, Scopus, Web of Science, ProQuest, and Google Scholar databases was conducted for reports on randomized controlled trials published up to October 2021.
Population characteristics and data on colonic transit time (CTT), stool consistency, defecation frequency, abdominal pain, bloating, flatulence, volunteer compliance, and adverse events were extracted. A random-effects model was used to estimate the effect of probiotic treatment on these variables.
In total, 1551 studies were identified, of which 14 were included in the qualitative synthesis and 13 in the meta-analysis. Overall, probiotic supplementation increased defecation frequency (standardized mean difference [SMD], 0.26; 95%CI, 0.13-0.39). Subgroup analysis revealed a decrease in CTT (SMD, -0.34; 95%CI, -0.62 to -0.07) in short-term treatment (≤14 d) and an improvement in stool consistency (SMD, 0.76; 95%CI, 0.44-1.08) in individuals without GIS. No improvement in abdominal pain and bloating was found.
B. animalis subspecies lactis supplementation may increase defecation frequency and, in short-term treatment, may reduce CTT in healthy adults and improve stool consistency in individuals without GIS. More high-quality randomized controlled trials are needed to develop a clinical protocol for the use of this strain to improve these symptoms.
PROSPERO registration no. CRD42020154060.
益生菌对胃肠道（GI）症状的影响已得到越来越多的研究，尤其是动物双歧杆菌。迄今为止，临床试验显示了关于这些影响在健康成年人中的不同证据。
综合已发表的关于动物双歧杆菌乳酸亚种对健康成年人胃肠道症状（GIS）影响的证据。
对Medline、Embase、Lilacs、Scopus、Web of Science、ProQuest和谷歌学术数据库进行检索，以获取截至2021年10月发表的随机对照试验报告。
提取人口统计学特征以及结肠转运时间（CTT）、粪便稠度、排便频率、腹痛、腹胀、肠胃气胀、志愿者依从性和不良事件的数据。采用随机效应模型估计益生菌治疗对这些变量的影响。
总共识别出1551项研究，其中14项纳入定性综合分析，13项纳入荟萃分析。总体而言，补充益生菌增加了排便频率（标准化均值差[SMD]，0.26；95%置信区间，0.13 - 0.39）。亚组分析显示，短期治疗（≤14天）时CTT降低（SMD，-0.34；95%置信区间，-0.62至-0.07），无GIS的个体粪便稠度改善（SMD，0.76；95%置信区间，0.44 - 1.08）。未发现腹痛和腹胀有所改善。
补充动物双歧杆菌乳酸亚种可能增加健康成年人的排便频率，在短期治疗中可能降低CTT，并改善无GIS个体的粪便稠度。需要更多高质量的随机对照试验来制定使用该菌株改善这些症状的临床方案。
PROSPERO注册号CRD42020154060。
